<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00111683</url>
  </required_header>
  <id_info>
    <org_study_id>0457-003</org_study_id>
    <secondary_id>2005_033</secondary_id>
    <nct_id>NCT00111683</nct_id>
  </id_info>
  <brief_title>MK0457 in Patients With Leukemia (0457-003)</brief_title>
  <official_title>A Phase I/II Dose Escalation Study of MK0457 in Patients With Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study participants with relapsed/refractory leukemia will be given MK-0457 in
      sequential cohorts and with varying treatment duration to determine the maximum tolerated
      dose (MTD) for MK-0457.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)</measure>
    <time_frame>Part 1: up to 5 days, Part 2: up to 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hematological response rate to MK-0457 as a 5-day CIV infusion</measure>
    <time_frame>At the end of each cycle (up to 18 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Chronic Myelogenous Leukemia in Blast Crisis</condition>
  <condition>Lymphocytic Leukemia, B Cell, Acute</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelogenous Leukemia, Chronic</condition>
  <arm_group>
    <arm_group_label>MK-0457</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive MK-0457 as a continuous intravenous infusion (CIV) at assigned dose and duration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0457</intervention_name>
    <arm_group_label>MK-0457</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Part 1:

          -  Patients with relapsed/refractory acute myelogenous leukemia (AML), poor risk
             myelodysplastic syndrome (MDS), B-cell acute lymphocytic leukemia (ALL),
             myeloproliferative diseases, or chronic myelogenous leukemia (CML) in blast crisis

        Part 2:

          -  Acute myelogenous leukemia (with FLT-3 mutation ), and myeloproliferative diseases
             only

          -  At least 2 weeks since the last cytotoxic therapy

          -  Acceptable renal and hepatic function

          -  Ambulatory, capable of all self-care, and out of bed for more than 50% of waking hours

          -  More than 2 months since autologous bone marrow or peripheral blood stem cell
             transplantation

        Exclusion Criteria:

          -  Not fully recovered from previous anti-leukemia therapy

          -  Previous allogeneic bone marrow transplant

          -  Uncontrolled congestive heart failure

          -  Myocardial infarction within the last 3 months

          -  Active or uncontrolled infection

          -  Pregnancy or lactation

          -  Currently active second malignancy, other than non-melanoma skin cancer

          -  History of hepatitis B or C, known HIV positivity, or AIDS related illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Giles FJ, Swords RT, Nagler A, Hochhaus A, Ottmann OG, Rizzieri DA, Talpaz M, Clark J, Watson P, Xiao A, Zhao B, Bergstrom D, Le Coutre PD, Freedman SJ, Cortes JE. MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. Leukemia. 2013 Jan;27(1):113-7. doi: 10.1038/leu.2012.186. Epub 2012 Jul 9.</citation>
    <PMID>22772060</PMID>
  </results_reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2005</study_first_submitted>
  <study_first_submitted_qc>May 24, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2005</study_first_posted>
  <last_update_submitted>August 21, 2015</last_update_submitted>
  <last_update_submitted_qc>August 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplastic Syndrome[Refractory Anemia with</keyword>
  <keyword>Excess Blasts-1 or 2 (WHO Classification)]</keyword>
  <keyword>Chronic Myelogenous Leukemia in blast crisis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
    <mesh_term>Leukemia, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

